Published in Br J Dermatol on July 01, 1987
Analysis of the age-related composition of human skin collagen and collagens synthesized by fibroblast culture. Arch Dermatol Res (1994) 0.78
Classical electrostatics in biology and chemistry. Science (1995) 17.26
Ankylosing spondylitis and HL-A 27. Lancet (1973) 11.99
Elective ventilation of potential organ donors. BMJ (1995) 5.50
Reiter's disease and HL-A 27. Lancet (1973) 4.10
Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int (1998) 4.03
Detection and characterisation of an overmodified type III collagen by analysis of non-cutaneous connective tissues in a patient with Ehlers-Danlos syndrome IV. J Med Genet (1992) 3.80
Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. Science (1991) 3.79
Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet (2000) 3.07
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Patients with Ehlers-Danlos syndrome type IV lack type III collagen. Proc Natl Acad Sci U S A (1975) 2.88
Fertilization and pregnancy after assisted oocyte activation and intracytoplasmic sperm injection in a case of round-headed sperm associated with deficient oocyte activation capacity. Fertil Steril (1997) 2.75
Acute anterior uveitis and HL-A 27. Lancet (1973) 2.74
THE MECHANISM OF DEATH FROM QUINIDINE AND A METHOD OF RESUSCITATION; AN EXPERIMENTAL STUDY. J Clin Invest (1925) 2.62
Extracting hydrophobic free energies from experimental data: relationship to protein folding and theoretical models. Biochemistry (1991) 2.46
A highly polymorphic region 3' to the human type II collagen gene. Nucleic Acids Res (1985) 2.37
Osteogenesis imperfecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation. J Biol Chem (1984) 2.25
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet (1990) 2.11
Long-range genomic map of the Duchenne muscular dystrophy (DMD) gene: isolation and use of J66 (DXS268), a distal intragenic marker. Genomics (1987) 1.89
Free-energy determinants of alpha-helix insertion into lipid bilayers. Biophys J (1996) 1.89
Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J (1973) 1.88
Automated ligand placement and refinement with a combined force field and shape potential. Acta Crystallogr D Biol Crystallogr (2006) 1.84
A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. Hum Mol Genet (1996) 1.81
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum. Am J Hum Genet (2001) 1.73
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet (1982) 1.69
HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet (1974) 1.68
Genetic linkage of the Muckle-Wells syndrome to chromosome 1q44. Am J Hum Genet (1999) 1.68
Phenotypical features of an unique Irish family with severe autosomal recessive osteogenesis imperfecta. Clin Genet (1989) 1.65
Historical evidence for the genetic heterogeneity of pseudoxanthoma elasticum. Br J Dermatol (1975) 1.59
Cerebrovascular disease in Ehlers-Danlos syndrome type IV. Stroke (1990) 1.58
The clinical features of homozygous alpha 2(I) collagen deficient osteogenesis imperfecta. J Med Genet (1984) 1.56
Two mutations in Marfan syndrome resulting in truncated fibrillin polypeptides. Proc Natl Acad Sci U S A (1992) 1.54
Single base mutation in the type III procollagen gene that converts the codon for glycine 883 to aspartate in a mild variant of Ehlers-Danlos syndrome IV. J Biol Chem (1989) 1.53
The molecular defect in a nonlethal variant of osteogenesis imperfecta. Synthesis of pro-alpha 2(I) chains which are not incorporated into trimers of type I procollagen. J Biol Chem (1983) 1.52
Linkage data for Marfan syndrome and markers on chromosomes 1 and 11. J Med Genet (1990) 1.52
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Inheritance of Ehlers-Danlos type IV syndrome. J Med Genet (1977) 1.47
COL2A1 exon 2 mutations: relevance to the Stickler and Wagner syndromes. Br J Ophthalmol (2000) 1.45
Some patients with cerebral aneurysms are deficient in type III collagen. Lancet (1981) 1.43
Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg (2014) 1.43
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 1.42
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
Type III collagen mutations in Ehlers Danlos syndrome type IV and other related disorders. Clin Exp Dermatol (1988) 1.38
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (2010) 1.34
Biochemical heterogeneity of osteogenesis imperfecta: New variant. Lancet (1979) 1.32
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
An exon skipping mutation of a type V collagen gene (COL5A1) in Ehlers-Danlos syndrome. J Med Genet (1996) 1.32
Lethal osteogenesis imperfecta congenita and a 300 base pair gene deletion for an alpha 1(I)-like collagen. Br Med J (Clin Res Ed) (1984) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Nuclease S1 mapping of a homozygous mutation in the carboxyl-propeptide-coding region of the pro alpha 2(I) collagen gene in a patient with osteogenesis imperfecta. Proc Natl Acad Sci U S A (1984) 1.29
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol (1996) 1.29
Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol (2000) 1.29
A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) (2002) 1.27
Organ donation. BMJ (1993) 1.27
A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. Am J Hum Genet (1998) 1.26
Ethics and elective ventilation. Br J Hosp Med (1994) 1.25
Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol (1994) 1.25
Effect of weight-loss on plasma and urinary levels of uric acid. Lancet (1972) 1.25
Pseudoxanthoma elasticum maps to an 820-kb region of the p13.1 region of chromosome 16. Genomics (1999) 1.24
Rheumatoid nodules: differential diagnosis and immunohistological findings. Ann Rheum Dis (1993) 1.23
Localized scleroderma and hemiatrophy in association with antibodies to double-stranded DNA. Postgrad Med J (1992) 1.23
COL3A1 mutations cause variable clinical phenotypes including acrogeria and vascular rupture. Br J Dermatol (1996) 1.22
Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis (2008) 1.19
An exclusion map of Marfan syndrome. J Med Genet (1990) 1.18
Clinical presentations of Ehlers Danlos syndrome type IV. Arch Dis Child (1988) 1.18
The antiperinuclear factor. Clin Exp Rheumatol (1991) 1.18
The gene responsible for Werner syndrome may be a cell division "counting" gene. Proc Natl Acad Sci U S A (1993) 1.17
Collagen deficiency and ruptured cerebral aneurysms. A clinical and biochemical study. J Neurosurg (1983) 1.17
Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol (1990) 1.16
The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum (2001) 1.15
The gene encoding collagen alpha1(V)(COL5A1) is linked to mixed Ehlers-Danlos syndrome type I/II. J Invest Dermatol (1996) 1.15
Linkage of a polymorphic marker for the type III collagen gene (COL3A1) to atypical autosomal dominant Ehlers-Danlos syndrome type IV in a large Belgian pedigree. Hum Genet (1988) 1.13
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis (2001) 1.13
EDS IV (acrogeria): new autosomal dominant and recessive types. J R Soc Med (1980) 1.12
A single base mutation in COL5A2 causes Ehlers-Danlos syndrome type II. J Med Genet (1998) 1.12
Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis (2002) 1.11
Clinical variability of osteogenesis imperfecta reflecting molecular heterogeneity: cysteine substitutions in the alpha 1(I) collagen chain producing lethal and mild forms. J Biol Chem (1986) 1.11
Molecular abnormalities of collagen: a review. J R Soc Med (1983) 1.10
Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev (2005) 1.10